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ABSTRACT
Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) are common causes of nephrot-
ic syndrome. These two conditions are similar in their presentations but differentiated via their histopathological 
features and responsiveness to corticosteroids. There are ongoing debates whether MCD and FSGS are at the same 
spectrum of disease rather than separate entities. FSGS has been postulated to be the severe end of the spectrum of 
MCD. We have reported a case that has primary FSGS after years of poorly controlled MCD, which supports both 
conditions are the same spectrum of disease.
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INTRODUCTION
Minimal change disease (MCD) is the most common 
cause for idiopathic nephrotic syndrome. MCD is 
characterized by heavy proteinuria that leads to 
intravascular volume depletion, hypoalbuminemia and 
edema. The presentation of MCD can be seen mostly 
in young children and some in adults. In peadiatric 
population, MCD accounts for almost 90% of cases 
in idiopathic nephrotic syndrome (1). In adults, MCD 
only accounts for 10 – 25% of cases. Other causes of 
nephrotic syndrome in adults that needs to be considered 
are FSGS or membranous nephropathy. MCD and focal 
segmental glomerulosclerosis (FSGS) are both examples 
of glomerulopathy that primarily affect the podocyte. 
Until recently, there has not been much report that show 
the progression of MCD into FSGS over the years. We 
report here a rare occurrence of FSGS in a patient who 
is known to have MCD.
CASE REPORT
Our patient is a 19-years-old teenager was diagnosed with 
MCD at the age of 9. He was started on prednisolone until 
the age of 15-year-old where he subsequently defaulted 
treatment. At the age of 16-year-old, he developed 
another episode of relapsed of nephrotic syndrome. 
Renal biopsy done confirmed the diagnosis of MCD. 
He was reinitiated on corticosteroids. Unfortunately, 
he defaulted all follow-ups and represented to us with 
relapsed of nephrotic-nephritc syndrome. His initial 
blood result shows: urea 20.7 mmol/L, creatinine 
522 μmol/L, albumin 7 g/L, urine analysis protein 
4+ and blood 1+ and urine protein creatinine ratio 
approximate to 24 gram of proteinuria per day. His 
baseline creatinine one year ago was 75 μmol/L. Renal 
biopsy was repeated and showed moderately advanced 
focal segmental glomerulosclerosis with 38% of global 
sclerosis evident. Immunofluorescence staining was 
negative for IgG, IgA, IgM, C3, C1q, fibrinogen, Kappa 
and Lambda. (Figure 1 and 2). Patient was restarted on 
diuretic and corticosteroids. Angiotensin converting 
enzyme inhibitor was subsequently added when renal 
function started to show improvement. He responded 
well with improvement in proteinuria and renal profile. 
His latest blood tests revealed serum creatinine153 
μmol/L, albumin 49 g/L and urine protein creatinine 
approximate to 0.9 gram of proteinuria per day.
DISCUSSION
MCD which is a major cause of idiopathic nephrotic 
syndrome presented with proteinuria, edema, 
intravascular depletion, and hypoalbuminemia with 
no glomerular lesions by light microscopy (or only 
minimal mesangial prominence), no staining on 
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immunofluorescence microscopy (or low intensity 
staining for C3 and IgM) and foot process effacement 
but no electro-dense deposits on electron microscopy. 
MCD in children usually responds to corticosteroid. 
Therefore, corticosteroid treatment has always been 
started in MCD without renal biopsy unless steroid 
resistance or alternative diagnosis is being considered. 
The underlying cause of MCD is associated with 
systemic T cell dysfunction resulting in production of 
a glomerular permeability factor (1). The factors will 
directly affect glomerular capillary wall causing marked 
proteinuria and fusion of foot process. There has always 
been a debate that MCD and FSGS falls within the same 
spectrum of disease or a separate pathogenetic entities. 
MCD will have full nephrotic syndrome, evidence 
of complete effacement of podocyte on electron 
microscopy, good response to immunosupressants and 
Figure1 :  Glomeruli show global sclerosis and segmen-
tal sclerosis (H and E)
Figure 2: Mild mesangial proliferation with focal synae-
chaeformation (H and E)
rarely progress to chronic kidney disease. 
On the other hand, FSGS is a disease entity defined by 
findings of sclerotic and non-sclerotic glomerular lesion 
on renal biopsy. FSGS alone can be classified as primary, 
secondary or genetic forms. Clinical presentation of 
primary FSGS or idiopathic FSGS is similar with MCD 
where patient presented with nephrotic syndrome. It 
has been hypothesized that the initial podocyte injury 
is the critical step that lead to potential progession to 
FSGS. The extent of this injury, the vulnerability of the 
podocytes, the presence of additional factors (such as 
diabetes and hypertension) and the response to therapy 
will determine whether FSGS lesions will develop or 
not.
Secondary FSGS will have non-nephrotic range 
proteinuria with certain degree of renal impairment and 
less clinical severity as compared with primary FSGS. 
This condition can be seen due to adaptive response 
to glomerular hypertrophy or hyperfiltration towards 
condition that causes reduction of nephron mass, scar 
from a healing inflammatory lesions or toxicity from drugs 
and viral infection. Genetic mutations in genes that codes 
for proteins expressed in podocytes and slit diaphragm 
can cause FSGS as well. Presentation of genetic cause 
of FSGS varies in terms of degree of proteinuria and 
nephrotic syndrome. Diagnosis of underlying cause and 
differentiating type of FSGS needs to be established to 
ensure the appropriate treatment. Postulated mechanism 
that leads to progression from MCD to FSGS when the 
patent has poorly controlled nephrotic syndrome include 
the persistent tubulointerstitial fibrosis and inflammation 
inflicted by the on-going proteinuria. Proteinuria can 
potentially contribute to the tubulointerstitial fibrosis 
by activation of the inflammatory and/or profibrotic 
pathways in tubular cells and injuring podocytes at the 
same setting (2).
Data from our Malaysia registry of renal biopsy 
(MRRB) (over a period of 7 years with 8,298 biopsies) 
showed that prevalence of MCD and FSGS from renal 
biopsies are 32% and 29% respectively for primary 
glomerulonephritis. The incidence of FSGS is peak at 
those patients aged15-25 years old and there after the 
incidence slowly deceased with advancing age.  In the 
registry, common presentation of FSGS include nephrotic 
syndrome (57.3%), asymptomatic urinary abnormalities 
(24.6%) and mixed nephritic-nephrotic at 5.7%. 
Contrary to common belief, it is not a benign disease 
as 15% of the patients were noted to have progressed 
to ESRD over a period of 72 months follow up. Up to 
a third of the patients were note to have suffered from 
hypertension at the time of diagnosis of FSGS (3).
Primary FSGS or idiopathic FSGS is highly associated 
with MCD.Our case shows similar findings of Tejani et 
al. where 15 patients out of 33 patients who has frequent 
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relapses from MCD, have progressed to FSGS (4).
Corticosteroid therapy as a mainstay of treatment for 
FSGS already has numerous report that supports the 
efficacy of it. A retrospective analysis shows 63% of 
patient attained remission after initiating corticosteroid. 
Another study reported 58% of the patients with biopsy 
proven FSGS responded well to corticosteroid. Overall 
remission rates of 57 – 66% have been reported with 
complete remission rates of 32% - 47% and partial 
remission rates of 19 – 29% (5). However, there are other 
advanced therapies for FSGS that can be considered 
if patient is not responding to corticosteroid therapy 
such as cyclophosphamide, calcineurin inhibitor, 
mycophenolate mofetil, mizoribine or biologic 
treatment.
CONCLUSION
We have shown that FSGS can arise from a poorly 
controlled MCD, thus supporting the notion that MCD 
and FSGS are the same spectrum of disease with FSGS 
being the severe form of the spectrum. In view of the 
poor prognosis of FSGS, attention must be given to MCD 
patients to ensure the optimal renal outcome.
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